



NEWSLETTER

September 2025

LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients: A Pilot Randomized Trial

A Message from the Principal Investigators

Dear friends,

We hope you all had a restful and enjoyable summer. It has been a busy time for WISDOM as recruitment has started at two centres in Edmonton. So far, we have gotten excellent feedback from the sites: the protocol has been deployed with minimal difficulty and data collection has gone smoothly.

St. Michael's Hospital has been activated, and Hamilton General will be activated soon. Thanks to Ellen, we are moving forward efficiently towards the launch of up to 15 sites in Canada, the US and the UK.

We are truly honoured to have you as our partners in this research program as we aim to answer a vital question of uncertainty in clinical nephrology.

As always, feel free to call us (Sean: 780-722-9756, Ron: 416-258-6540) or send us an email with any questions that you may have.


Sean and Ron



Site Start-Up and Activation

Enrollment for the WISDOM study began in November 2024 at the University of Alberta (UAH) and Mazankowski Heart Research Institute (MAZ) sites. St Michael's Hospital opened for enrollment as of September 2025. There are 9 other sites that are working on site start-up activities, including sites in the UK and the US. We anticipate several Canadian sites to be open to enrollment shortly.

Enrollment Updates



Target enrollment is 100 participants. To date, the University of Alberta Hospital has enrolled 11 participants, and the Mazankowski Alberta Heart Institute has enrolled 12 participants for a total enrollment of 23 participants.

Reminders

- ◆ Please remember to submit your screening logs through the REDCap regulatory database on the first business day of each month.
- ◆ Monitoring will be initiated after the first five participants are enrolled at your site or one year after your site's activation, whichever occurs first.
- ◆ Study details, current documents, FAQs and study updates can be found on the [WISDOM](#) website.



Questions? Please contact us!

Co-Chairs:

Sean Bagshaw, MD MSc FRCPC FCAHS

Department of Critical Care Medicine
Faculty of Medicine and Dentistry, University of Alberta,
Edmonton, Canada

T: (587) 984-4662

E: bagshaw@ualberta.ca

Ron Wald, MDCM MPH FRCPC

Division of Nephrology, Department of Medicine, St. Michael's
Hospital and the University of Toronto, Toronto, Canada

T: (416) 867-3707

E: Ron.Wald@unityhealth.to

Project Manager:

Ellen Morrison, PhD

Clinical Trials Office (CTO), Faculty of Medicine and Dentistry,
College of Health Sciences, University of Alberta

T: (780) 289-4890

E: ellen.morrison@ualberta.ca

**THANK YOU FOR YOUR CONTINUED PARTICIPATION IN THE WISDOM
TRIAL!**